ARAdelaida Ruseva

Adelaida Ruseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adelaida Ruseva has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laboratory diagnosis of primary hyperparathyroidism in patients with nephrolithiasis

    by Mihaela Atanasova, Jitian Atanasov, Nikolay Garev, Adelaida Ruseva

    Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by inappropriate secretion of parathyroid hormone (PTH), resulting in hypercalcemia and disturbances in calcium-phosphate metabolism. Nephrolithiasis represents one of the most frequent and clinically significant renal manifestations of the disease and may serve as an early indicator of PHPT. This review summarizes the current diagnostic approach to PHPT in patients presenting with nephrolithiasis, with particular emphasis on laboratory evaluation. Key biochemical parameters, including serum calcium, ionized calcium, parathyroid hormone, phosphate, vitamin D status, and urinary calcium excretion, are discussed in the context of diagnosis, differential diagnosis, and postoperative follow-up. Special attention is given to the differentiation between PHPT, familial hypocalciuric hypercalcemia, and secondary hyperparathyroidism. In addition, the review outlines the complementary role of imaging modalities in preoperative localization and discusses the indications for parathyroidectomy in patients with renal involvement. An integrated clinical, laboratory, and imaging approach is essential for accurate diagnosis, risk stratification, and individualized management of patients with PHPT-associated nephrolithiasis.

  • Open Access

    Glucocorticoid Resistance in COVID-19: Endocrine–Inflammatory Associations in a Cross-Sectional Study

    by Malvina Todorova, Victoria Tsvetkova, Milena Atanasova, Adelaida Ruseva, Katya Todorova

    Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation and immune dysregulation, potentially affecting hypothalamic–pituitary–adrenal (HPA) axis function and glucocorticoid signaling. However, the dynamics and clinical relevance of these alterations across different disease phases remain insufficiently defined. In this cross-sectional observational study, 101 participants were divided into three groups: patients with active COVID-19 (n = 33), individuals ≥ 6 months post-COVID-19 (n = 35), and a reference group of healthy individuals (n = 33). Serum cortisol, circulating glucocorticoid receptor alpha (GRα), and selected cytokines were measured. Statistical analysis included parametric and non-parametric tests, multivariable generalized linear models adjusted for age and sex, correlation analysis, and receiver operating characteristic (ROC) analysis. Lower serum cortisol levels were observed in approximately two-thirds of patients during the acute phase. Circulating GRα concentrations demonstrated a significant gradient across groups, with the lowest levels in active infection and partial restoration post-COVID. Active COVID-19 status remained independently associated with reduced GRα levels after adjustment for age and sex. The cytokine profile, including interleukin-17A (IL-17A), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10), provided a mechanistic context for inflammation-associated modulation of glucocorticoid signaling, most evident during acute infection. Significant correlations between cortisol, GRα, and inflammatory mediators were observed only in this phase. ROC analysis demonstrated a high degree of statistical separation between active COVID-19 and healthy individuals (AUC 0.942; 95% CI: 0.878–1.000). Given the predefined group structure and modest sample size, these findings should be considered exploratory. Overall, the results support the presence of dynamic and potentially reversible immune–endocrine dysregulation during and after SARS-CoV-2 infection. Further validation in larger prospective cohorts is required.


  • IL-6, D-DIMER AND HIGH-SENSITIVITY C-REACTIVE PROTEIN IN HIV INFECTION – PRELIMINARY STUDY

    by Ivaylo Pakov, Adelaida Ruseva, Irena Gencheva, Tsetsa Doichinova, Milena Karcheva, Kalina Terzieva, Lyudmila Pakova, Biserka Vasileva, Galya Gancheva

  • ADAPTED MEDITERRANEAN DIET IMPACT ON THE SYMPTOMS OF CHRONIC FATIGUE, SERUM LEVELS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS (PUFAS) AND INTERLEUKIN 17 (IL-17) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS UNDERGOING DISEASE-MODIFYING THERAPY: A PILOT STUDY

    by Emiliya Ovcharova, Maya Danovska, Diana Marinova, Diana Pendicheva-Duhlenska, Pencho Tonchev, Milena Atanasova, Adelaida Ruseva, Nicholas Shepherd, Reni Tzveova

    Purpose: This pilot study was designed to investigate the impact of a moderate-calorie Mediterranean diet compared to a regular diet with omega-3 PUFAs (eicosapentaenoic and docosahexaenoic acids) supplementation on fatigue symptoms in patients with relapsing-remitting multiple sclerosis (RRMS) and to assess the optional benefit of the diet on their quality of life. Material/Methods: This 12-month pilot study was conducted in 2021 at the Department of Neurology, Medical University – Pleven, Bulgaria. A total of 60 patients with RRMS aged 18-64 were selected from the database of the Neurology Clinic at the University Hospital "Dr Georgi Stranski" – Pleven. From the selected patients, only 30 were included in the pilot phase and respectively assigned to the nutritional arms. Blood samples were collected twice – at the first and second visit in 3 months, for metabolic and dietary parameters analysis. Symptoms of fatigue were assessed with Fatigue Scale for Motor and Cognitive Functions (FSMC) and Modified Fatigue Impact Scale (MFIS). Results: From the 30 participants included in the study, 17 patients attended the clinic centre for complete follow-up; the remaining 13 were only partially observed. The dynamics of the followed-up parameters showed a statistically significant change in the body mass index (BMI), the fatigue symptoms in the FSMC and MFIS scales, total cholesterol and triglycerides levels, and the serum concentrations of IL17A, EPA and DHA. The metabolic caloric values were also found to be significantly changed. Conclusions: Despite the small study size limitation, this pilot study might be of benefit for further extensive research on the potential favorable impact of diet and lifestyle modifications on the symptoms of fatigue in multiple sclerosis patients.